Nedocromil

Summary

Nedocromil (CHEMBL746) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC R01AC07); indicated across 4 conditions including eye allergy and obstructive lung disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R01AC07 (+2 more)
• Indications: 4 conditions
• Clinical trials: 3
• Chemistry: 371.3 Da · C19H17NO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL746
Name	Nedocromil
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	50294
ChEBI	CHEBI:7492
ATC	R01AC07, R03BC03, S01GX04
Molecular formula	C19H17NO7
Molecular weight	371.3
InChIKey	RQTOOFIXOKYGAN-UHFFFAOYSA-N

SMILES: CCCC1=C2C(=CC3=C1OC(=CC3=O)C(=O)O)C(=O)C=C(N2CC)C(=O)O

IUPAC name: 9-ethyl-4,6-dioxo-10-propylpyrano[3,2-g]quinoline-2,8-dicarboxylic acid

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, anti-asthmatic drug, anti-allergic agent.

Also known as: FPL 59002, FPL-59002, Nedocromil, Nedocromilo, NEDOCROMIL, SID144206699, SID170464978, Nedocromil sodium, nedocromil

Parent form; salt/anhydrous children: CHEMBL915, CHEMBL2105133

Patent coverage: 3,270 distinct patent families (14,058 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 13,948 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye allergy	4	MONDO:0005551	EFO:0005751
obstructive lung disease	4	MONDO:0002267	HP:0006536
asthma	3	MONDO:0004979	MONDO:0004979

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000575	PHASE3	COMPLETED	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)
NCT01061333	PHASE1	COMPLETED	Early Airway Response to Allergen in Asthmatics (MK-0000-176)
NCT00135681	Not specified	COMPLETED	Immune Dysregulation in Children and Adults With Asthma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).